Managing Labor with each Contraction

PreTel Solutions



PreTel’s area sensor uterine electromyography (uEMG) monitoring solves the inability of existing technology to accurately identify independent contraction activity of individual regions of the uterus. Identification of this regional activity allows for improved care in the preterm labor patient, managing the progress of labor at time of delivery, and safety to the admiration of induction therapy.

These improvements will avoid unnecessary C-Section deliveries, post-delivery maternal hemorrhage, and expensive neonatal intensive care nursery stays.

PreTel Monitoring Systems

PreTel pregnancy monitoring systems integrate the reporting of fetal heart rate (FHR), maternal heart rate (MHR), contraction activity and individual region activity into a portable patient wearable device. System solutions include interface to existing hospital central monitoring hardware and cloud access for home monitoring applications.

The PreTel pregnancy monitoring system improves both maternal and neonatal outcomes in the labor and delivery department, across hospital systems and throughout integrated health care networks.

PreTel Area Sensors

Pregnancy monitoring impacts 3.7 Million births (US) improving both maternal and neonatal outcomes.


Regional uterine monitoring results in:

Supports preterm labor management

Evaluates therapy response

Accurate antepartum assessment

Differentiates false from true labor contractions

Labor progress information

Avoids unnecessary induction or C-section

Safely conducts induction therapy

Avoids tachysystole

PreTel area sensors provide new information

Measure regional uterine synchronization

Indicates type of contraction

Evaluates progress of labor

Increase/decrease of synchronization

Additional Observations & Measurements

Evaluation of oxytocin induction during contraction rest periods

Technology Advantages

Wearable Area Sensor technology provides the determination of the amount of individual regions of the uterus that make up each contraction. This unique uterine EMG technique is combined with fetal and maternal ECG monitoring in the PreTel Juno Pregnancy Monitoring System. The PreTel Juno Pregnancy Monitoring Systems not commercially available for sale.


Advantages over traditional
monitoring systems:

  • Wearable Sensor Array
    Avoids the need for sensor repositioning by L&D staff
  • Bluetooth Data Transmission
    Allows patient mobility by eliminating sensor cords
  • Integrates Uterine Activity, Fetal and Maternal Heart Rate Monitoring
    Eliminate need for multiple monitoring devices

Advantages over standard
EMG monitoring systems:

  • Directional Regional Uterine Activity Sensor
    Identifies individual regions of contraction activity
  • Proprietary Regional Activity Assessment
    Determines regional coordination and synchronization

PreTel Clinical Management Advantages:

  • Reporting of Regional Progress to Coordination and Synchronization
  • Evaluates preterm labor therapy response
  • Improves antepartum assessment of true and false labor contractions
  • Identifies progress and lack of labor progress to delivery
  • Identifies precursor to tachysystole during induction delivery


News

PreTeL, Inc. to Present at the 2022 Society for Maternal Fetal Medicine 42nd Annual Pregnancy Meeting

Chattanooga, TN —December 10, 2021 - PreTeL, Inc., a rapidly emerging Femtech company focusing on improving the lives of expectant mothers and women in labor announced today that its abstract “EMG provides insights into preterm birth: Mid-trimester cervical shortening is associated with abnormal myometrial activation” will be presented during the initial Plenary Session at the Society of Maternal Fetal Medicine’s (SMFM) 42nd Annual Pregnancy Meeting to be held January 1- February 5, 2022 in Orlando, Florida. The PreTeL Labor Status Monitor utilizes a proprietary “Uterine Area Sensor” designed specifically to record local electromyographic (EMG) activities produced by small regions of the pregnant uterus.

Dr. Roger Young, Chief Medical Officer at PreTeL says, “Mid-trimester cervical shortening is an excellent screening tool that can identify patients who are at risk for delivering preterm. However, being able to classify patients as high-risk raises three crucial questions: Who needs intervention? What intervention is most appropriate? When should the intervention be performed? The EMG data we present are physiological changes that complement the anatomic findings, and define a pathway to answering at least one, and perhaps all three questions.”

Marc Finch, CEO added “Our abstract was judged as 3rd best worth of a plenary presentation, indicating maternal fetal medicine specialists desire to learn more about our technology and to support its further development. Our goal is to reduce the likelihood of a preterm birth for those at risk for preterm delivery, such as those with short cervix diagnosed in early pregnancy. While the expenses associated with a preterm birth are ten to fifty times those of a term delivery, permanent disabilities such as cerebral palsy, chronic respiratory disorders, cognitive delay and visual and hearing disorder occur much more often in preterm babies.”

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTel, Inc. to Present at the 2021 Society for Maternal Fetal Medicine Annual Meeting

Chattanooga, TN —January 26, 2021 - PreTel, Inc., a rapidly emerging Femtech company focusing on improving the lives of expectant mothers and women in labor. announced today that data from its unique preterm labor test will be presented at the Society of Maternal Fetal Medicine’s (SMFM) annual meeting to be held January 25-30. The PreTel test utilizes a proprietary “Uterine Area Sensor” technology for electromyography (EMG) signal detection and isolation for preterm labor diagnosis and management.

“By using our sensors and analysis, we are able to distinguish true from false labor with high specificity. We anticipate this diagnostic tool will dramatically improve the management of preterm and term women who present in threatened labor,” added Dr. Roger Young, Chief Medical Office at PreTel. “Pretel’s approach is revolutionary, since for the first time, Uterine Area Sensors are used to isolate the EMG signals from specific locations on the uterus. Through a proprietary analysis, the local uterine bioactivities are then processed to detect both the strong contractions of true labor and novel signals that indicate false labor.”

Marc Finch, CEO added “We are developing this technology to provide physicians the opportunity to rapidly intervene when preterm labor is diagnosed. Our goal is to reduce the likelihood of a preterm birth for those in true labor and avoid unnecessary hospitalization for those in false labor. While the expenses associated with a preterm birth are ten to fifty times those of a term delivery, permanent disabilities such as cerebral palsy, chronic respiratory disorders, cognitive delay and visual and hearing disorder occur much more often in preterm babies.”

The poster presentation “Distinguishing true from false labor with a novel labor test” (#553) at the SMFM annual meeting will occur at 8:30 am EDT on Friday, January 29th for all attendees to this year’s virtual meeting. (It can be view on www.pretelhealth.com immediately after the presentation.)

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTel Names Femtech Leader Mark A. Samuels as Executive Chair

Chattanooga, TN —January 15, 2021 - PreTel, Inc., a rapidly emerging private Femtech company focusing on improving the lives of expectant mothers and women in labor, has appointed Mark A. Samuels as Executive Chairman of its Board of Directors.

Mr. Samuels has extensive experience in the medical device sector and served as President and CEO of OBMedical Company from 2016 to 2018 prior to its acquisition by Phillips Medical. OBMedical’s products included an FDA cleared, wireless electrode-based maternal-fetal monitor for measuring labor contractions and fetal heart rate. Mr. Samuels previously led the development and commercialization of various medical device technologies across women’s health and maternal-infant care for cancer detection, breast cancer imaging and serum bilirubin detection.

Mr. Samuels will be working with PreTel’s CEO, Marc Finch, and founder Roger Young, MD, PhD, to guide the continued development of targeted uterine myography monitoring and intelligent analysis to improve pregnancy, labor and delivery outcomes.

“I believe PreTel represents a significant opportunity to improve the health and safety of mothers and babies during pregnancy and labor using its advanced technology platform aimed at predicting labor, monitoring the progress of labor and adjusting Pitocin drug delivery,” said Mr. Samuels. “About 40% of all women in the United States experience false labor at a very high financial and emotional cost. PreTel’s technology has the potential to significantly improve the ability of healthcare professionals to respond appropriately.”

“Mark’s addition to the PreTel team comes at a critical time as we prepare to convert our proprietary system of uterine myography signal detection and intelligent analysis for preterm labor diagnosis and maternal and fetal safety during labor and delivery into bedside monitoring. His successes in the launch of new medical technology solutions into the health care system and understanding of the maternal fetal care delivery space will be instrumental in establishing key partnerships to ensure our success,” said Marc Finch, CEO.

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com

PreTel Selected to Present at ADVANSE Life Sciences Conference

Chattanooga, TN —October 15, 2021 - PreTel, Inc., a rapidly emerging private Femtech company focusing on improving the lives of expectant mothers and women in labor, has been selected to present to investor attendees at the ADVANSE Life Sciences Conference highlighting advances in Biopharma, Medtech, Diagnostic and Digital Health.

PreTeL will present its patented uterine EMG technology that through digital signal analytics determines true from false labor in high-risk preterm patients. Founder Roger Young, MD, PhD, commented “Our clinical studies show that improving ECG/EMG signal acquisition and using advanced analytics translates into new solutions for pregnancy management that fulfill long-standing clinical needs. We envision a trio of solutions such as preterm labor diagnosis, labor induction oxytocin (Pitocin) dosing support, and preterm fetal monitoring.”

Marc Finch, CEO, indicated “There are over 1.3 million trips to the ER ever year for preterm contractions, in which diagnostic accuracy is only 30%. Incorrect diagnosis result in unnecessary hospitalization or failure to provide therapeutic steroid therapy critical to the health of the preterm infant. Our Labor Status Monitor will improve accuracy to over 80% greatly improving neonatal health. PreTeL’s platform of monitors will expand the scope of pregnancy monitoring of the 3.5 million pregnancies every year by providing new methods of diagnosis and therapy dosing support. Our goals are to simultaneously reduce human suffering of mother and baby and reduce health care costs of pregnancy, ultimately becoming the leading provider of pregnancy monitoring”

Marc Finch, will present PreTel to ADVANSE investor attendees Thursday October 28th.

About PreTel

PreTel, Inc. is a private, US-based Femtech company recognized for its innovative work in novel uterine electromyography (uEMG) signal detection and intelligent analysis for the large maternal-fetal medicine markets of both remote and hospital care. The company’s proprietary “Area Sensor” platform is being developed for early warning monitoring for pregnancies that may result in spontaneous preterm birth, labor and delivery care, and the personalized dosing of Pitocin during labor induction to optimize pregnancy care of both mother and baby. For more information, please visit www.pretelhealth.com.

Corporate Contact: Marc Finch, 423.243.3460, info@pretelhealth.com



The pretel Team

We are a team of professionals, dedicated to improving the health of women and babies by expanding their options with innovative medical devices that provide significant clinical impact.

Roger Young, MD

Founder
READ BIO

Mark Samuels

Executive Chairman
READ BIO

Marc Finch

CEO
READ BIO

Dave Adair, MD

Board Member
READ BIO

Blake Patton

Board Member
READ BIO